The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Johnson & Johnson
Patents, Royalties, Other Intellectual Property - GlaxoSmithKline; Janssen Research & Development
 
Research Funding - Abbvie (Inst); BeiGene (Inst); BMS Brazil (Inst); Genentech (Inst); Janssen (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); QED Therapeutics (Inst); Seagen (Inst)
(OPTIONAL) Uncompensated Relationships - Association of American Cancer Institutes (Inst); Precision Oncology Alliance/Caris Life Sciences (Inst)
Lorpucitinib (JNJ-64251330) in patients with familial adenomatous polyposis (FAP): Results from a phase 1b study.
 
Robert Hüneburg
Honoraria - Janssen
Consulting or Advisory Role - Fujifilm; One Two Therapeutics
Research Funding - Janssen (Inst)
 
Marcia Cruz-Correa
No Relationships to Disclose
 
Evelien Dekker
Consulting or Advisory Role - Ambu; CPP-FAP; Fujifilm; GI Supply; Olympus Medical Systems; PAION AG
Speakers' Bureau - Fujifilm; GI Supply; IPSEN; Norgine; Olympus; PAION AG
Research Funding - Fujifilm (Inst)
 
Gregory Idos
No Relationships to Disclose
 
Daniel A. Sussman
No Relationships to Disclose
 
Eduardo Vilar Sanchez
Consulting or Advisory Role - Guardant Health; Janssen Research & Development; Recursion Pharmaceuticals
Research Funding - Janssen Research & Development
Patents, Royalties, Other Intellectual Property - The University of Texas MD Anderson Cancer Center, Vilar E, Chang K, Wu W, Bowen CM, Sinha K. Methods and Compositions Comprising MHC Class I Peptides, United States, 63/171,137, 4/6/2021, Filed (Provisional); The University of Texas MD Anderson Cancer Center, Vilar E, Wu W, Katayama H, Hanash S, Bommi P. Methods for Prognosing, Diagnosing, and Treating Colorectal Cancer, United States, 63/152,751, 2/23/2021, Filed (Provisional)
Travel, Accommodations, Expenses - Guardant Health; Janssen Research & Development
 
Francesc Balaguer
Consulting or Advisory Role - Elsevier; One-two therapeutics; Persei Vivarium
 
Hyun Jung Lee
No Relationships to Disclose
 
Tae IL Kim
No Relationships to Disclose
 
Jeong-Sik Byeon
No Relationships to Disclose
 
Philippe Grandval
Consulting or Advisory Role - Boston Scientific
Research Funding - Janssen (Inst)
 
N. Jewel Samadder
Consulting or Advisory Role - Cancer Prevention Pharmaceuticals; Janssen Research & Development; Recursion Pharmaceuticals
 
Jacob Nattermann
Research Funding - Fujifilm
 
Arthur S. Aelvoet
Research Funding - Janssen (Inst)
 
James G. Greger
No Relationships to Disclose
 
Vincent Lin
Employment - Johnson & Johnson/Janssen
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
 
Gary V. Borzillo
Employment - Janssen
Stock and Other Ownership Interests - GlaxoSmithKline; Johnson & Johnson; Vertex
 
Madhu Sanga
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Janssen Research & Development
 
Edward F. Attiyeh
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson
Patents, Royalties, Other Intellectual Property - Johnson & Johnson